FDA flags dosing risks from compounded versions of Novo’s weight-loss drug

SILVER SPRING, Md. — The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs.

The health regulator said it had received reports of adverse events, some requiring…